Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8317190 | 0.90 | NOS2 (0.58) | ALDH1A1NR4A2CYP4F2CYP4A11FAAH | |
| SCHEMBL2582728 | 0.86 | TACR1 (0.51) | ALDH1A1CYP4F2CYP4A11FAAHOPRD1 | |
| SCHEMBL6042553 | 0.84 | OPRL1 (0.66) | ALDH1A1FAAHOPRL1 | |
| SCHEMBL6584414 | 0.83 | CYP4F2 (0.51) | NR4A2CYP4F2CYP4A11ADAM17MAOB | |
| SCHEMBL2959082 | 0.83 | CYP4F2 (0.51) | NR4A2CYP4F2CYP4A11ADAM17MAOB | |
| SCHEMBL2579926 | 0.81 | OPRD1 (0.48) | ALDH1A1ADAM17OPRM1OPRD1OPRK1 | |
| SCHEMBL18656530 | 0.81 | S1PR5 (0.45) | ALDH1A1NR4A2ABCB1MAOB | |
| SCHEMBL2588266 | 0.81 | ALDH1A1 (0.73) | ALDH1A1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL9217663 | 0.80 | ALOX5 (0.61) | ALDH1A1 | |
| SCHEMBL4407004 | 0.79 | MEN1 (0.47) | ALDH1A1CYP4F2CYP4A11OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859777-B2 | 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators | KINENTIA BIOSCIENCES LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137331-A2 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | OPRD1, OPRK1, OPRM1 | ALDH1A1 1107/4885NR4A2 523/4885CYP4F2 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.